Metsera Presents Clinical and Preclinical Data at EASD Annual Meeting.

Metsera, Inc. will present clinical and preclinical data at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD). The data highlights the potential of the company's ultra-long acting next-generation nutrient-stimulated hormone therapies as monotherapies and in combination with each other. The late-breaker presentation showcases initial clinical results for MET-233i, an ultra-long acting amylin analog, and two preclinical presentations will also be featured.

Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company, will present clinical and preclinical data at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), scheduled from September 15-19, 2025, in Vienna, Austria. The company aims to showcase the potential of its ultra-long acting next-generation nutrient-stimulated hormone (NuSH) therapies, both as standalone treatments and in combination with each other.

The late-breaking presentation, titled "Pharmacokinetics, weight loss, and tolerability of the ultra-long acting amylin analog MET-233 (LB 14)," will feature initial clinical results for MET-233i, an ultra-long acting amylin analog. This presentation is set to take place on Wednesday, September 17, 2025, from 2:30 to 4:00 PM CEST in the London Hall Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting^[1].

In addition to the late-breaking presentation, Metsera will present two preclinical studies. The first, titled "Therapeutic NuSH cocktails: co-administration of an ultra-long acting PYY analogue engineered for tolerability and an ultra-long acting GLP-1 analogue induces significant weight loss in DIO mice (786)," will be presented on Thursday, September 18, 2025, from 2:00 to 3:00 PM CEST in Event F, Station 11 Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting^[1]. The second preclinical study, titled "MET-233 is a differentiated efficacious amylin analogue in preclinical studies, combinable with MET-097, an ultra-long acting GLP-1 receptor agonist (224)," will be presented on Friday, September 19, 2025, from 10:00 to 11:00 AM CEST in the Paris Hall Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting^[1].

These presentations highlight Metsera's progress in developing ultra-long acting, scalable, and combinable therapies to address obesity and metabolic diseases. The company's Chief Medical Officer, Steve Marso, M.D., expressed optimism about the potential of these therapies, noting their ability to be used both as monotherapies and in combination Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting^[1].

Metsera, founded in 2022, is advancing a broad portfolio of oral and injectable incretin, non-incretin, and combination therapies with potential best-in-class profiles. The company's mission is to meet the future needs of a rapidly evolving weight loss treatment landscape.

The presentations at EASD 2025 are part of Metsera's ongoing efforts to accelerate the development of next-generation medicines for obesity and metabolic diseases. The company's forward-looking statements are subject to risks and uncertainties, including those related to its business and regulatory progress Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting^[2].

For more information about Metsera, please visit their website at www.metsera.com or follow them on LinkedIn and X.